The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2023 | Targeting EGFR-positive NSCLC with antibody-drug conjugates
Jorge Nieva, MD, University of California, San Francisco, CA, comments on the promising role of antibody-drug conjugates (ADCs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). There are very limited options for patients who have progressed on third generation EGFR inhibitors, and ADCs represent a potential strategy for this group of patients. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
